HDAC10 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL28250	0.57	14/20
SCHEMBL29476	0.57	14/20
SCHEMBL31064	0.57	14/20
SCHEMBL30259	0.57	14/20
SCHEMBL28328	0.61	13/20
SCHEMBL28329	0.61	13/20
SCHEMBL28330	0.61	13/20
SCHEMBL29695	0.61	13/20
SCHEMBL30199	0.61	13/20
Vorinostat (SCHEMBL9018)	1.00	12/20
SCHEMBL34229	0.51	12/20
Iodipamide (SCHEMBL37678)	0.41	12/20
Trichostatin (SCHEMBL19886)	1.00	10/20
SCHEMBL19539	0.48	10/20
SCHEMBL28840	0.61	9/20
SCHEMBL28841	0.61	9/20
SCHEMBL28842	0.61	9/20
SCHEMBL29955	0.61	9/20
SCHEMBL29956	0.61	9/20
SCHEMBL21138	0.49	9/20

Clinical trials — most relevant to HDAC10 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab	PHASE1/PHASE2	RECRUITING
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma	PHASE2	COMPLETED
Vorinostat in Children	PHASE1/PHASE2	COMPLETED
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes	PHASE1/PHASE2	COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer	PHASE2	UNKNOWN
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS	PHASE2	COMPLETED
Chidamide Combined With Toripalimab in Sarcoma	PHASE2	COMPLETED
Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors	PHASE1/PHASE2	UNKNOWN
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma	PHASE2	COMPLETED
LRAs United as a Novel Anti-HIV Strategy.	PHASE1/PHASE2	COMPLETED
Voronistat in Pediatric Patients With Drug Resistant Epilepsy	PHASE2	UNKNOWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Safety and Pharmacokinetic Profile of CKD-581	PHASE1	COMPLETED
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers	PHASE1	COMPLETED
Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia	PHASE1	COMPLETED
Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction	PHASE1	COMPLETED
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors	PHASE1	COMPLETED
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors	PHASE1	COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE1	UNKNOWN
Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid	EARLY_PHASE1	COMPLETED
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia	nan	RECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome	nan	UNKNOWN
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
Chi-GVM Regimen for the Treatment of R/R PTCL	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a HDAC10 binder may also engage these)

Protein	Name	Similarity
Q6P3E7	—	0.991	Q6P3E7 →
Q569C4	—	0.990	Q569C4 →
Q8IVS8	—	0.970	Q8IVS8 →
Q32M88	—	0.970	Q32M88 →
Q6XQN1	—	0.968	Q6XQN1 →
Q8CC86	—	0.965	Q8CC86 →
Q8BZG5	—	0.965	Q8BZG5 →
Q59I47	—	0.965	Q59I47 →
HDHD5	Haloacid dehalogenase-like hydrolase domain-containing 5	0.963	landscape →
TRPM4	Transient receptor potential cation channel subfamily M member 4	0.963	landscape →
Q8BP56	—	0.963	Q8BP56 →
Q2KJF7	—	0.962	Q2KJF7 →
Q8QZY2	—	0.962	Q8QZY2 →
Q0VGK3	—	0.962	Q0VGK3 →
Q53HV7	—	0.961	Q53HV7 →
GPAA1	GPI-anchor transamidase component GPAA1	0.960	landscape →
Q9JIW4	—	0.960	Q9JIW4 →
Q3T0A0	—	0.960	Q3T0A0 →
Q91WM2	—	0.959	Q91WM2 →
Q6AYG0	—	0.959	Q6AYG0 →
Q5H879	—	0.959	Q5H879 →
Q9ESQ5	—	0.959	Q9ESQ5 →
Q96EY9	—	0.959	Q96EY9 →
Q9JIA7	—	0.959	Q9JIA7 →
O60294	—	0.959	O60294 →
Q0V8F1	—	0.959	Q0V8F1 →
Q5E9V4	—	0.958	Q5E9V4 →
Q561R2	—	0.958	Q561R2 →
PKN3	Serine/threonine-protein kinase N3	0.958	landscape →
Q8VD52	—	0.958	Q8VD52 →